Engineered immune cells join forces to fight leukemia
NCT ID NCT03984968
First seen May 11, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study tests a new approach for adults with a specific type of leukemia (Philadelphia chromosome-positive B-ALL). It combines two types of engineered immune cells: CAR-T cells that attack cancer, and 'feeding' T cells that help the CAR-T cells grow and stay active longer. The goal is to see if this combination is safe and can lead to a complete molecular response, meaning no detectable cancer genes. About 40 participants will receive up to four cycles of this therapy after standard chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT B-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
Conditions
Explore the condition pages connected to this study.